<DOC>
	<DOCNO>NCT02148185</DOCNO>
	<brief_summary>The purpose study evaluate PK , PD safety single oral dose MT-1303 subject Crohn 's disease .</brief_summary>
	<brief_title>Pharmacokinetics ( PK ) , Pharmacodynamics ( PD ) Safety Study MT-1303 Subjects With Crohn 's Disease</brief_title>
	<detailed_description>This Phase I , open-label , non-randomised , multicenter single-dose study evaluate PK , PD , safety single oral dose MT-1303 subject moderate severe active Crohn 's disease ( ileal ileo-colonic type ) .</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>Subjects diagnose Crohn 's disease Subjects confirm ileal ileocolonic type image inspection . Disease severity determine either `` moderate '' `` severe '' Present past history gastrointestinal surgery may impact drug absorption Subjects stenosis fistula small intestine colon</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Crohn 's disease</keyword>
</DOC>